Cycloheximide (Naramycin A) 是一种抗真菌 (antifungal) 抗生素，是真核生物蛋白质合成 (protein synthesis) 的抑制剂，抑制体内蛋白质合成和 RNA 合成的 IC50 值分别为 532.5 nM 和 2880 nM。Cycloheximide 可抑制铁死亡 (ferroptosis) 并抑制自噬 (autophagy)。
| CAS No. | 66-81-9 |
| 生物活性 | Cycloheximide (Naramycin A), an antifungal antibiotic, is an eukaryote protein synthesis inhibitor, with IC50s of 532.5 nM and 2880 nM for protein synthesis and RNA synthesis in vivo, respectively. Cycloheximide suppresses ferroptosis and inhibits autophagy. |
| 分子式 | C15H23NO4 |
| 分子量 | 281.35 |
| 运输条件 | Room temperature in continental US; may vary elsewhere. |
| 储存条件 | 4°C, protect from light |
| 溶解性数据 | DMSO : 125 mg/mL (444.29 mM; Need ultrasonic) H2O : 20 mg/mL (71.09 mM; Need ultrasonic and warming) |
| 体内研究 | The mice receive Cycloheximide injections at 30, 60, or 120 mg/kg prior to training with a 200 µA shock. There is a significant effect of Cycloheximide on latencies on the memory test trials (P<0.001). In saline controls, this shock level results in latencies on the test trial that are significantly higher than those at training. Injections of the lowest dose of Cycloheximide tested, 30 mg/kg, results in latencies on the test trial that are significantly higher than those seen in the saline control group. Mice receiving either of the two higher doses of Cycloheximide has latencies on the test trial that are comparable to those of the saline group, i.e., the higher doses neither enhanced nor impaired memory under these conditions, resulting in an inverted-U dose-response curve for Cycloheximide enhancement of memory. Infarct volume, as measured by morphometric analysis of infarct areas with triphenyl tetrazolium chloride (TTC), is significantly reduced by 92% and 61% when Cycloheximide is given 0 or 6 hr after HI respectively, but shows an insignificant trend in infarct reduction if Cycloheximide is administered 12 hr after hypoxia-ischemia (HI) compared to the HI control group, and no protective effect is observed when administration is delayed until 24 hr after HI. |
| 体外研究 | Cycloheximide (CHX) is the most common laboratory reagent used to inhibit protein synthesis. Cycloheximide has been shown to block the elongation phase of eukaryotic translation. Cycloheximide binds the ribosome and inhibits eEF2-mediated translocation. Surprisingly, Cycloheximide allows one complete translocation cycle to proceed before halting any further elongation. Cycloheximide has been speculated that Cycloheximide requires an E-site bound deacylated tRNA for activity. |
| 文献 | •Cell. 2019 Dec 12;179(7):1566-1581.e16. •Immunity. 2018 Jul 17;49(1):80-92.e7. •Cell Metab. 2021 May 4;33(5):971-987.e6. •Cell Metab. 2021 Jan 5;33(1):110-127.e5. •Cell Res. 2020 Sep;30(9):779-793. •J Hepatol. 2020 May;72(5):976-989. •Blood. 2021 Mar 18;137(11):1478-1490. •Signal Transduct Target Ther. 2020 Dec 26;5(1):298. •Mol Cell. 2021 Aug 19;81(16):3339-3355.e8. •Mol Cell. 2021 Apr 1;81(7):1425-1438.e10. •Mol Cell. 2020 Jan 2;77(1):95-107.e5. •J Hematol Oncol. 2018 Feb 23;11(1):26. •Circ Res. 2018 May 25;122(11):1532-1544. •Nucleic Acids Res. 2020 May 21;48(9):4858-4876. •Nucleic Acids Res. 2019 Sep 5;47(15):8239-8254. •Adv Sci (Weinh). 2021 Aug;8(15):e2100606. •Adv Sci (Weinh). 2021 Mar 24;8(10):2003404. •Adv Sci (Weinh). 2021 Feb 8;8(8):2002874. •Adv Sci (Weinh). 2019 Mar 25;6(10):1801862. •Autophagy. 2021 Dec 10;1-19. •Autophagy. 2021 Aug 25;1-22. •Autophagy. 2021 Jul;17(7):1592-1613. •Autophagy. 2020 Jan;16(1):154-166. •Autophagy. 2021 Feb;17(2):457-475. •Autophagy. 2020 Apr;16(4):641-658. •Autophagy. 2018;14(12):2155-2170. •Cell Host Microbe. 2020 Jan 8;27(1):115-128.e8. •Cell Death Differ. 2022 Jan 15. •Cell Death Differ. 2021 Nov 6. •Cell Death Differ. 2021 Jul 2. •Cell Death Differ. 2021 Jul;28(7):2221-2237. •Cell Death Differ. 2021 Jan;28(1):337-348. •Cell Death Differ. 2020 Jan;27(1):55-70. •Mol Cancer. 2020 Nov 23;19(1):163. •Mol Cancer. 2019 Apr 18;18(1):89. •Nat Chem Biol. 2021 May;17(5):576-584. •Nat Commun. 2021 Jul 20;12(1):4413. •Nat Commun. 2021 Jun 3;12(1):3319. •Nat Commun. 2021 May 14;12(1):2809. •Nat Commun. 2021 May 10;12(1):2587. •Nat Commun. 2019 Dec 2;10(1):5492. •Nat Commun. 2019 Sep 19;10(1):4266. •Protein Cell. 2021 Feb;12(2):107-127. •Cancer Res. 2021 Sep 15;81(18):4778-4793. •Cancer Res. 2019 Feb 1;79(3):534-545. •Dev Cell. 2020 May 4;53(3):287-299.e5. •Dev Cell. 2019 Feb 25;48(4):460-474.e9. •Redox Biol. 2020 Nov 1;38:101771. •Redox Biol. 2019 Jun;24:101211. •Theranostics. 2021 Jun 11;11(16):7640-7657. •Theranostics. 2021 Apr 15;11(13):6278-6292. •Theranostics. 2021 Jan 1;11(2):841-860. •Theranostics. 2020 May 16;10(14):6483-6499. •Theranostics. 2020 Jul 9;10(19):8573-8590. •Theranostics. 2019 Aug 12;9(20):5769-5783. •Theranostics. 2019 Jul 9;9(17):4878-4892. •Theranostics. 2018 Feb 15;8(7):2044-2060. •Clin Transl Med. 2020 Dec;10(8):e240. •Mol Ther. 2020 May 6;28(5):1299-1313. •Acta Pharm Sin B. 2021 Jan;11(1):71-88. •Acta Pharm Sin B. 2019 May;9(3):526-536. •J Exp Clin Cancer Res. 2021 Aug 27;40(1):273. •J Exp Clin Cancer Res. 2021 May 10;40(1):162. •J Exp Clin Cancer Res. 2021 May 7;40(1):158. •J Exp Clin Cancer Res. 2021 Jun 23;40(1):206. •J Exp Clin Cancer Res. 2019 Feb 26;38(1):101. •J Exp Clin Cancer Res. 2019 Feb 15;38(1):83. •J Exp Clin Cancer Res. 2018 Nov 27;37(1):287. •Oncogene. 2021 Oct 14. •Oncogene. 2021 Sep 23. •Oncogene. 2021 Jul 14. •Oncogene. 2021 Jan;40(1):163-176. •Oncogene. 2020 Aug;39(34):5633-5648. •Oncogene. 2020 May;39(19):3926-3938. •Oncogene. 2019 Sep;38(37):6429-6444. •Diabetes. 2021 Feb 24;db201008. •Cell Rep. 2020 Dec 22;33(12):108544. •Cell Rep. 2020 Aug 4;32(5):107990. •Aging Cell. 2021 Nov 22;e13522. •Cell Mol Life Sci. 2022 Jan 12;79(1):70. •Genet Med. 2019 Dec;21(12):2744-2754. •Mol Ther-Nucl Acids. 2021 Feb 3;24:436-448. •Br J Pharmacol. 2020 Jan;177(2):432-448. •Exp Mol Med. 2022 Jan 14. •Cancer Lett. 2021 Nov 16;S0304-3835(21)00581-4. •Cancer Lett. 26 July 2021. •Cancer Lett. 2021 Jun 10;517:14-23. •Cancer Lett. 2020 Feb 28;471:103-115. •Cancer Lett. 2020 Jan 28;469:287-300. •Cell Death Dis. 2022 Jan 10;13(1):42. •Cell Death Dis. 2021 Oct 2;12(10):902. •Cell Death Dis. 2021 May 8;12(5):462. •Cell Death Dis. 2021 Mar 12;12(3):265. •Cell Death Dis. 2021 Mar 3;12(3):229. •Cell Death Dis. 2021 Jan 7;12(1):42. •Cell Death Dis. 2021 Jan 11;12(1):60. •Cell Death Dis. 2020 Dec 2;11(12):1032. •Cell Death Dis. 2020 Sep 24;11(9):798. •Cell Death Dis. 2020 Apr 17;11(4):242. •Cell Death Dis. 2020 Apr 24;11(4):281. •Cell Death Dis. 2019 Aug 5;10(8):583. •Cell Death Dis. 2019 Aug 8;10(8):599. •Cell Death Dis. 2018 Oct 12;9(10):1046. •Cell Death Dis. 2018 May 22;9(6):604. •Cell Death Dis. 2018 May 3;9(5):519. •Cell Death Dis. 2017 Sep 14;8(9):e3048. •Antioxid Redox Signal. 2019 May 20;30(15):1831-1848. •Environ Health Perspect. 2019 Dec;127(12):127006. •Environ Health Perspect. 2019 Dec;127(12):127006. •JCI Insight. 2021 Oct 8;6(19):e145172. •EBioMedicine. 2019 Oct;48:236-247. •EBioMedicine. 2018 Aug;34:243-255. •Mbio. 2021 Aug 10;e0198521. •Pharmacol Res. 2022 Jan 5;106059. •Pharmacol Res. 2021 Sep 6;105870. •Pharmacol Res. 2020 Jul;157:104845. •Front Immunol. 2021; 12: 724403. •Oncogenesis. 2020 Apr 29;9(4):42. •Oncogenesis. 2020 Mar 12;9(3):34. •Int J Cancer. 2020 Jul 1;147(1):175-188. •Int J Cancer. 2020 Apr 1;146(7):1963-1978. •Free Radic Biol Med. 14 January 2022. •Free Radic Biol Med. 2021 Apr 22;S0891-5849(21)00265-3. •Free Radic Biol Med. 2020 Dec;161:187-197. •Mol Ther Oncolytics. 11 November 2021. •Genes Dis. 2020 Nov 21;8(6):867-881. •Gene Dis. 2019 May 25;7(3):401-407. •Chemosphere. 2021 Feb;264(Pt 1):128440. •Int J Biol Macromol. 2021 Apr 14;S0141-8130(21)00832-1. •NPJ Breast Cancer. 2022 Jan 10;8(1):2. •PLoS Pathog. 2021 Jun 2;17(6):e1009645. •PLoS Pathog. 2021 Mar 4;17(3):e1009370. •PLoS Pathog. 2019 Feb 25;15(2):e1007382. •PLoS Pathog. 2017 Jun 19;13(6):e1006449. •Cell Oncol. 2020 Dec;43(6):1099-1116. •Cell Oncol. 2020 Feb;43(1):65-80. •Cell Biol Toxicol. 2021 Nov 25. •Front Cell Dev Biol. 2020 May 7;8:287. •Front Cell Dev Biol. 2019 Oct 2;7:217. •Mol Oncol. 2021 May;15(5):1566-1583. •Int J Biol Sci. 2021; 17(9):2167-2180. •Int J Biol Sci. 2019 Aug 8;15(10):2139-2155. •Oxid Med Cell Longev. 2020 Oct 23;2020:2048210. •Transl Lung Cancer Res. 2020 Dec;9(6):2337-2355. •Breast Cancer Res. 2021 Dec 18;23(1):116. •Plant J. 2019 Apr;98(1):71-82. •Int J Nanomedicine. 2020 Aug 26;15:6503-6518. •Ecotoxicol Environ Saf. 25 December 2021, 113028. •J Mol Cell Biol. 2021 Oct 21;13(7):527-539. •Am J Cancer Res. 2020 Oct 1;10(10):3440-3457. •Am J Cancer Res. 2019 Oct 1;9(10):2249-2263. •Acta Pharmacol Sin. 2021 Apr 6. •Acta Pharmacol Sin. 2021 Aug;42(8):1298-1310. •Acta Pharmacol Sin. 2020 Aug 11. •Cancer Gene Ther. 2021 Feb 8. •Biochem Pharmacol. 2020 Oct;180:114118. •Biochem Pharmacol. 2020 Jul;177:113947. •Biochem Pharmacol. 2020 Jan;171:113715. •Mol Cancer Res. 2020 Feb;18(2):204-215. •Cancer Cell Int. 2022 Jan 6;22(1):7. •Cancer Cell Int. 2021 Nov 27;21(1):631. •Cancer Cell Int. 2020 Jun 3;20:212. •Cancer Cell Int. 2020 Jun 24;20:271. •Neoplasia. 2020 Jun 26;22(9):343-351. •Cell Commun Signal. 2021 Mar 15;19(1):33. •Cell Commun Signal. 2019 Dec 27;17(1):173. •Cell Commun Signal. 2019 Jan 14;17(1):4. •Aging. 2021 Mar 24;13(7):10312-10325. •Aging. 2020 Dec 11;13(2):1947-1961. •Aging. 2020 Dec 9;13(2):2436-2458. •Aging. 2020 Oct 25;12(20):20047-20068. •Int J Oncol. 2020 Jan;56(1):232-242. •Int J Oncol. 2020 Jan;56(1):232-242. •FEBS J. 2021 Jan 25. •J Transl Med. 2021 Jun 17;19(1):264. •Stem Cells Int. 23 Nov 2021. •J Immunol. 2020 Aug 15;205(4):1135-1146. •J Immunol. 2020 May 1;204(9):2589-2599. •J Cell Mol Med. 2020;00:1-11. •J Cell Mol Med. 2020 Dec 27. •J Cell Mol Med. 2020 Jul;24(14):8221-8235. •Cell Death Discov. 2021 Dec 4;7(1):374. •Cell Death Discov. 2021 Dec 14;7(1):389. •Cell Death Discov. 2021 Sep 16;7(1):242. •Cell Death Discov. 2021 Jul 27;7(1):196. •Chem Biol Interact. 2022 Jan 5;109798. •Chem Biol Interact. 2021 Oct 27;109729. •Chem Biol Interact. 2018 Mar 1;283:59-74. •FASEB J. 2019 Dec;33(12):14296-14306. •PLoS Genet. 2021 Apr 26;17(4):e1009514. •J Biol Chem. 2020 Oct 2;295(40):13798-13811. •J Biol Chem. 2019 Dec 27;294(52):20164-20176. •J Biol Chem. 2019 Nov 29;294(48):18504-18515. •J Biol Chem. 2019 Jul 19;294(29):11119-11130. •Arthritis Res Ther. 2020 Nov 16;22(1):269. •J Virol. 2019 Jun 14;93(13):e00588-19. •J Virol. 2019 May 1;93(10):e02227-18. •J Virol. 2019 Jan 17;93(3). pii: e01899-18. •J Virol. 2018 Apr 27;92(10). pii: e00238-18. •Life Sci. 2021 Dec 16;289:120231. •Life Sci. 2020 Sep 1;256:117983. •Life Sci. 2020 Apr 1;246:117419. •Int Immunopharmacol. 2021 Apr 28;97:107688. •Int Immunopharmacol. 2020 Jan;78:106003. •Mol Carcinog. 2021 Feb 26. •RNA Biol. 2021 Jan 21;1-16. •Front Genet. 2020 Sep 2;11:536221. •J Proteome Res. 2021 Aug 22. •Eur J Pharmacol. 2020 Nov 5;886:173526. •BMC Cancer. 2021 Nov 5;21(1):1181. •J Mol Med. 2020 Jun;98(6):907-921. •J Mol Med (Berl). 2019 Aug;97(8):1183-1193. •Bone. 2020 Jun;135:115326. •Sci Rep. 2020 Jun 30;10(1):10604. •Sci Rep. 2020 May 22;10(1):8485. •Sci Rep. 2019 May 29;9(1):8034. •J Ethnopharmacol. 2021 Sep 3;114583. •Biochim Biophys Acta. 2016 Dec;1859(12):1527-1537. •Virol Sin. 2021 May 27. •Am J Pathol. 2020 Dec;190(12):2464-2477. •Biol Reprod. 2021 Mar 5. •Cancer Biol Med. 2021 Feb 15; 18(1): 227–244. •Toxicol Appl Pharmacol. 31 December 2021, 115857. •J Cancer. 2021 Sep 21;12(22):6727-6739. •J Cancer. 2021 Feb 22;12(8):2317-2325. •J Cancer. 2021 Jan 1;12(4):976-987. •FEBS Lett. 2020 Feb;594(3):497-508. •Environ Toxicol. 2021 Dec 7. •Int J Mol Med. August 20, 2021. •Int J Mol Med. 2020 Jun;45(6):1783-1792. •J Proteomics. 2020 Jan 6;210:103545. •Cancer Manag Res. 2020 Nov 6;12:11371-11382. •Ann Transl Med. 2020 Oct;8(20):1304. •J Alzheimers Dis. 2020;76(2):491-504. •Oncol Rep. August 9, 2021. •Oncol Rep. 2021 Feb 3. •Oncol Rep. 2020 Jun;43(6):2028-2044. •Exp Cell Res. 28 August 2021, 112799. •Exp Cell Res. 2020 Oct 1;395(1):112188. •Exp Cell Res. 2020 Sep 1;394(1):112118. •Exp Cell Res. 2020 May 15;390(2):111942. •Cytokine. 2022 Jan 5;151:155789. •Immunol Lett. 2021 Apr 22;S0165-2478(21)00064-X. •Pancreatology. 2021 Feb 12. •Biochem Biophys Res Commun. 20 August 2021. •Biochem Biophys Res Commun. 2019 Feb 12;509(3):797-802. •Biochem Biophys Res Commun. 2017 Sep 2;490(4):1168-1175. •Biomed Res Int. 2016;2016:8145495. •Exp Mol Pathol. 2020 Dec;117:104525. •Mil Med Res. 2021 Dec 9;8(1):63. •DNA Cell Biol. 2017 Jul;36(7):589-595. •Vet Microbiol. 2019 Dec;239:108456. •Eur J Histochem. 2021 Dec 7;65(4). •Oncol Lett. October 21, 2021. •Oncol Lett. 2018 Nov;16(5):5900-5906. •Appl Biochem Biotechnol. 2021 Nov 26. •Virology. 2019 Apr;530:51-58. •FEBS Open Bio. 2020 Sep;10(9):1810-1820. •Insect Mol Biol. 2020 Feb;29(1):104-111. •Int Dairy J. 2020, 104943. •Blood Cell Mol Dis. 2021 Feb;86:102490. •Mol Genet Genomic Med. 2021 Aug 7;e1771. •Int J Insect Sci. 2020 Sep 1;20(5):18. •Research Square Preprint. 2022 Jan. •Research Square Preprint. 2021 Dec. •Research Square Preprint. 2021 Nov. •Research Square Preprint. 2021 Aug. •STAR Protoc. 2021 Jun 17;2(3):100616. •bioRxiv. 2021 May 26. •Research Square Preprint. 2020 Nov. •Research Square Preprint. 2020 Sep. •Science in Biology. 2020, 28090044. •Research Square Preprint. 2020 Jul. •Fish Shellfish Immunol. 2019 Sep;92:889-896. •Patent. US20180263995A1. •bioRxiv. May 24, 2018. •Oncotarget. 2018 Jan 4;9(20):15239-15251. •Oncotarget. 2016 May 10;7(19):27176-84. |
| 纯度及产品资料 | 98% |
邮箱：info@TianyaBio.com
电话：020-3107 8154
地址：广州市番禺区兴业大道东路1078号2-50
微信公众号
微信客服
